PreciseDx is led by the foremost experts in the use of artificial intelligence in systems pathology. The Company’s leaders have deep expertise in diagnostics, pathology, innovative technology, and business and are further supported by a world-renowned Clinical Advisory Board comprised of distinguished clinicians.
Wayne Brinster is Chief Executive Officer of PreciseDx, and is a recognized, successful serial CEO. Prior to joining PreciseDx in 2021, Wayne was President and CEO of MedTest, where he orchestrated a complete business reorganization to align with a more strategic, market-focused vision and growth strategy. Prior to MedTest, Wayne was President and CEO of Wheaton Industries / DWK for five years where he led a major company restructuring, including new acquisitions and European expansion, generating sales growth and EBITDA improvement. Both assignments resulted in successful exits to market leading strategic purchasers. Prior positions include Vice President and General Manager of the Cancer Diagnostic group, where he led the worldwide effort to develop and release several diagnostic tests for cancer using both imaging and molecular markers. Wayne had full P&L responsibility for R&D, Regulatory, Quality, Sales, Marketing and Supply Chain management. Additional positions include Vice President and General Manager at Becton Dickinson and Vice President of Growth and Strategy at BD Diagnostics. Wayne holds a Bachelor of Science from the University of Miami, as well as several commercial board and leadership positions.
Dr. Zeineh is a co-founder and currently Chief Technology Officer of PreciseDx, where he brings deep expertise in microscopy technology research and development. Prior to his role at PreciseDx, Dr. Zeineh held a number of technology leadership positions, including CSO for Clarient, CTO/CSO for Carl Zeiss Microimaging AIS, CIO for Aureon Biosciences, and co-founder of Trestle Corporation. Dr. Zeineh graduated Summa Cum Laude from the University of California at Irvine in Biological Sciences, and received his medical degree from the University of California at San Diego. He is also a prolific inventor and holds more than 30 patents and patent applications.
Dr. Fernandez is a co-founder and currently Chief Scientific Officer of PreciseDx, in addition to his position as Adjunct Associate Professor in the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at the Mount Sinai Health System. He received his medical degree from Drexel University College of Medicine and completed his residency in anatomic and clinical pathology as well as fellowships in surgical pathology and cytopathology from New York University School of Medicine.
Dr. Fernandez has spent the last seven years as Associate Professor at Mount Sinai building and developing the PreciseDx team and platform. Before that, he was in industry as the Medical Director for Roche Tissue Diagnostics’ (Ventana) Digital Pathology group, Vice President for Pathology and Research and Development at Aureon Biosciences, and a Staff Pathologist at Genzyme Genetics, where he specialized in oncologic pathology and tissue biomarkers.
Dr. Donovan is a co-founder of PreciseDx, and currently serves as Vice-chair and Professor of Translational Research in the Department of Pathology at the University of Miami. In addition to a previous academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years of experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals.
Most recently, he has served as Chief Medical Officer of Renalytix, Chief Clinical Officer of Vigilant Biosciences, Inc., Chief Medical Officer of MetaStat, Inc., and Chief Medical Officer of Exosome Diagnostics, Inc. Dr. Donovan earned his Bachelor of Science degree in Zoology, a Master of Science degree in Endocrinology, and a PhD in Cell and Developmental Biology from Rutgers University. He received his medical degree from the Rutgers New Jersey Medical School.
Andrew Borsanyi is an experienced finance, medical technology, and real estate executive. He has led two firms to over $12 million revenues including oversight of finance, marketing, sales, product development and operations. Andrew has advised on over $10 billion of financial and real estate transactions.
From 2005-2019, Andrew was Principal and owner of The Concord Group, a top real estate finance advisory firm. At Concord, Andrew focused on the firm’s financial services and branded residential businesses. Andrew’s clients included the top private equity, financial institutions and developers in the world. Andrew participated in all aspects of firm management including finance and operations. Concord had a three-fold revenue increase and completed over 5,000 assignments during Andrew’s tenure in leadership.
From 1999-2004, Andrew was President and founder of Trestle Corporation, a medical technology firm. Trestle was a leader in digital pathology solutions with clients including Pfizer, MD Anderson, the US Army and the government of Saudi Arabia. Andrew led Trestle from start up, through capital raises, to over $10 million annual revenue and sale to Zeiss Microsystems. Prior to Trestle, Andrew worked at McKinsey and Company and Morgan Stanley.
Andrew has an M.B.A. from Harvard Business School and a B.A. in History from Wesleyan University. He was U.S. National Debate Champion as an undergraduate. Andrew enjoys skiing, cycling, travel, reading and etymology.
Dr. Cordon-Cardo is a co-founder and Chairman of the Advisory Board of PreciseDx, and currently serves as Professor and Chair System-Wide of the Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai Health System. From 1987 to 2006 Dr. Cordon-Cardo was a faculty member in the Department of Pathology at Memorial Sloan-Kettering Cancer Center, where he created the Division of Molecular Pathology and served as its first Director; scaling the academic ranks from Assistant to Professor of Pathology at Weill Cornell Medical College, Cornell University.
A pioneer of the oncologic molecular pathology discipline, Dr. Cordon-Cardo has helped establish a deeper understanding of the mechanisms of human cancers and new targets for cancer therapeutics, enhancing the vision of personalized medicine. Dr. Cordon-Cardo earned his medical degree from the Autonomous University of Barcelona (1980), and his PhD in Cell Biology and Genetics from Cornell University (1985).